What is the projected market valuation for the Pulmonary Embolism Therapeutics Market in 2035?

The Pulmonary Embolism Therapeutics Market is projected to reach a valuation of 2.394 USD Billion by 2035. Read More

What was the market valuation for the Pulmonary Embolism Therapeutics Market in 2024?

In 2024, the market valuation for the Pulmonary Embolism Therapeutics Market was 1.272 USD Billion. Read More

What is the expected CAGR for the Pulmonary Embolism Therapeutics Market during the forecast period 2025 - 2035?

The expected CAGR for the Pulmonary Embolism Therapeutics Market during the forecast period 2025 - 2035 is 5.92%. Read More

Which companies are considered key players in the Pulmonary Embolism Therapeutics Market?

Key players in the market include Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson, Sanofi, Roche, AstraZeneca, Novartis, GSK, and Pfizer. Read More

What are the main treatment types in the Pulmonary Embolism Therapeutics Market?

The main treatment types include Anticoagulants, Thrombolytics, and Mechanical Thrombectomy. Read More

What was the market size for Anticoagulants in 2024?

In 2024, the market size for Anticoagulants was 0.765 USD Billion. Read More

How does the market size for Patients With Symptomatic Pulmonary Embolism compare to other patient populations?

The market size for Patients With Symptomatic Pulmonary Embolism was 0.765 USD Billion, which is higher than the 0.382 USD Billion for Patients With Asymptomatic Pulmonary Embolism. Read More

What is the projected market size for Oral drug administration in 2035?

The projected market size for Oral drug administration is expected to reach 0.212 USD Billion by 2035. Read More

Which end-use sector is expected to dominate the Pulmonary Embolism Therapeutics Market?

The Hospitals sector is expected to dominate the Pulmonary Embolism Therapeutics Market, with a projected size of 1.455 USD Billion by 2035. Read More

What is the anticipated market size for Direct Oral Anticoagulants (DOACs) in 2035?

The anticipated market size for Direct Oral Anticoagulants (DOACs) is projected to be 0.95 USD Billion by 2035. Read More

Pulmonary Embolism Therapeutics Market

ID: MRFR/HC/25979-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Pulmonary Embolism Therapeutics Market Research Report By Treatment Type (Anticoagulants, Thrombolytics, Mechanical Thrombectomy), By Patient Population (Patients With Symptomatic Pulmonary Embolism, Patients With Asymptomatic Pulmonary Embolism, Patients With High-Risk Pulmonary Embolism), By Drug Route of Administration (Intravenous, Subcutaneous, Oral), By Drug Type (Direct Oral Anticoagulants (DOACs), Heparins, Vitamin K Antagonists), By End-Use Sector (Hospitals, Clinics, Ambulatory Surgical Centers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Treatment Type (USD Billion)
  1. 4.1.1 Anticoagulants
  2. 4.1.2 Thrombolytics
  3. 4.1.3 Mechanical Thrombectomy
2. 4.2 Healthcare, BY Patient Population (USD Billion)
  1. 4.2.1 Patients With Symptomatic Pulmonary Embolism
  2. 4.2.2 Patients With Asymptomatic Pulmonary Embolism
  3. 4.2.3 Patients With High-Risk Pulmonary Embolism
3. 4.3 Healthcare, BY Drug Route of Administration (USD Billion)
  1. 4.3.1 Intravenous
  2. 4.3.2 Subcutaneous
  3. 4.3.3 Oral
4. 4.4 Healthcare, BY Drug Type (USD Billion)
  1. 4.4.1 Direct Oral Anticoagulants (DOACs)
  2. 4.4.2 Heparins
  3. 4.4.3 Vitamin K Antagonists
5. 4.5 Healthcare, BY End-Use Sector (USD Billion)
  1. 4.5.1 Hospitals
  2. 4.5.2 Clinics
  3. 4.5.3 Ambulatory Surgical Centers
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Boehringer Ingelheim (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Roche (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 GSK (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Pfizer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY PATIENT POPULATION
5. 6.5 US MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
6. 6.6 US MARKET ANALYSIS BY DRUG TYPE
7. 6.7 US MARKET ANALYSIS BY END-USE SECTOR
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
9. 6.9 CANADA MARKET ANALYSIS BY PATIENT POPULATION
10. 6.10 CANADA MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
11. 6.11 CANADA MARKET ANALYSIS BY DRUG TYPE
12. 6.12 CANADA MARKET ANALYSIS BY END-USE SECTOR
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY PATIENT POPULATION
16. 6.16 GERMANY MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
17. 6.17 GERMANY MARKET ANALYSIS BY DRUG TYPE
18. 6.18 GERMANY MARKET ANALYSIS BY END-USE SECTOR
19. 6.19 UK MARKET ANALYSIS BY TREATMENT TYPE
20. 6.20 UK MARKET ANALYSIS BY PATIENT POPULATION
21. 6.21 UK MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
22. 6.22 UK MARKET ANALYSIS BY DRUG TYPE
23. 6.23 UK MARKET ANALYSIS BY END-USE SECTOR
24. 6.24 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY PATIENT POPULATION
26. 6.26 FRANCE MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
27. 6.27 FRANCE MARKET ANALYSIS BY DRUG TYPE
28. 6.28 FRANCE MARKET ANALYSIS BY END-USE SECTOR
29. 6.29 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY PATIENT POPULATION
31. 6.31 RUSSIA MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
32. 6.32 RUSSIA MARKET ANALYSIS BY DRUG TYPE
33. 6.33 RUSSIA MARKET ANALYSIS BY END-USE SECTOR
34. 6.34 ITALY MARKET ANALYSIS BY TREATMENT TYPE
35. 6.35 ITALY MARKET ANALYSIS BY PATIENT POPULATION
36. 6.36 ITALY MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
37. 6.37 ITALY MARKET ANALYSIS BY DRUG TYPE
38. 6.38 ITALY MARKET ANALYSIS BY END-USE SECTOR
39. 6.39 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY PATIENT POPULATION
41. 6.41 SPAIN MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
42. 6.42 SPAIN MARKET ANALYSIS BY DRUG TYPE
43. 6.43 SPAIN MARKET ANALYSIS BY END-USE SECTOR
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY PATIENT POPULATION
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY DRUG TYPE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY END-USE SECTOR
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TREATMENT TYPE
51. 6.51 CHINA MARKET ANALYSIS BY PATIENT POPULATION
52. 6.52 CHINA MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
53. 6.53 CHINA MARKET ANALYSIS BY DRUG TYPE
54. 6.54 CHINA MARKET ANALYSIS BY END-USE SECTOR
55. 6.55 INDIA MARKET ANALYSIS BY TREATMENT TYPE
56. 6.56 INDIA MARKET ANALYSIS BY PATIENT POPULATION
57. 6.57 INDIA MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
58. 6.58 INDIA MARKET ANALYSIS BY DRUG TYPE
59. 6.59 INDIA MARKET ANALYSIS BY END-USE SECTOR
60. 6.60 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY PATIENT POPULATION
62. 6.62 JAPAN MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
63. 6.63 JAPAN MARKET ANALYSIS BY DRUG TYPE
64. 6.64 JAPAN MARKET ANALYSIS BY END-USE SECTOR
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY PATIENT POPULATION
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY DRUG TYPE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY END-USE SECTOR
70. 6.70 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY PATIENT POPULATION
72. 6.72 MALAYSIA MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
73. 6.73 MALAYSIA MARKET ANALYSIS BY DRUG TYPE
74. 6.74 MALAYSIA MARKET ANALYSIS BY END-USE SECTOR
75. 6.75 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY PATIENT POPULATION
77. 6.77 THAILAND MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
78. 6.78 THAILAND MARKET ANALYSIS BY DRUG TYPE
79. 6.79 THAILAND MARKET ANALYSIS BY END-USE SECTOR
80. 6.80 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY PATIENT POPULATION
82. 6.82 INDONESIA MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
83. 6.83 INDONESIA MARKET ANALYSIS BY DRUG TYPE
84. 6.84 INDONESIA MARKET ANALYSIS BY END-USE SECTOR
85. 6.85 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY PATIENT POPULATION
87. 6.87 REST OF APAC MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
88. 6.88 REST OF APAC MARKET ANALYSIS BY DRUG TYPE
89. 6.89 REST OF APAC MARKET ANALYSIS BY END-USE SECTOR
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY PATIENT POPULATION
93. 6.93 BRAZIL MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
94. 6.94 BRAZIL MARKET ANALYSIS BY DRUG TYPE
95. 6.95 BRAZIL MARKET ANALYSIS BY END-USE SECTOR
96. 6.96 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY PATIENT POPULATION
98. 6.98 MEXICO MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
99. 6.99 MEXICO MARKET ANALYSIS BY DRUG TYPE
100. 6.100 MEXICO MARKET ANALYSIS BY END-USE SECTOR
101. 6.101 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY PATIENT POPULATION
103. 6.103 ARGENTINA MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
104. 6.104 ARGENTINA MARKET ANALYSIS BY DRUG TYPE
105. 6.105 ARGENTINA MARKET ANALYSIS BY END-USE SECTOR
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT POPULATION
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USE SECTOR
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY PATIENT POPULATION
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DRUG TYPE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY END-USE SECTOR
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY PATIENT POPULATION
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DRUG TYPE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY END-USE SECTOR
122. 6.122 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY PATIENT POPULATION
124. 6.124 REST OF MEA MARKET ANALYSIS BY DRUG ROUTE OF ADMINISTRATION
125. 6.125 REST OF MEA MARKET ANALYSIS BY DRUG TYPE
126. 6.126 REST OF MEA MARKET ANALYSIS BY END-USE SECTOR
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY PATIENT POPULATION, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY PATIENT POPULATION, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY DRUG ROUTE OF ADMINISTRATION, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY DRUG ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY END-USE SECTOR, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY END-USE SECTOR, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.2.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.3.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.3.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.4.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.4.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.5.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.5.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.6.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.6.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.7.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.7.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.8.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.8.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.9.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.9.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.10.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.10.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.11.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.11.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.12.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.12.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.13.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.13.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.14.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.14.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.15.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.15.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.16.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.16.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.17.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.17.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.18.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.18.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.19.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.19.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.20.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.20.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.21.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.21.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.22.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.22.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.23.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.23.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.24.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.24.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.25.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.25.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.26.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.26.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.27.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.27.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.28.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.28.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.29.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.29.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  3. 7.30.3 BY DRUG ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY DRUG TYPE, 2025-2035 (USD Billion)
  5. 7.30.5 BY END-USE SECTOR, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Pulmonary Embolism Therapeutics Market Segmentation

Pulmonary Embolism Therapeutics Market By Treatment Type (USD Billion, 2025-2035)

Anticoagulants
Thrombolytics
Mechanical Thrombectomy

Pulmonary Embolism Therapeutics Market By Patient Population (USD Billion, 2025-2035)

Patients With Symptomatic Pulmonary Embolism
Patients With Asymptomatic Pulmonary Embolism
Patients With High-Risk Pulmonary Embolism

Pulmonary Embolism Therapeutics Market By Drug Route of Administration (USD Billion, 2025-2035)

Intravenous
Subcutaneous
Oral

Pulmonary Embolism Therapeutics Market By Drug Type (USD Billion, 2025-2035)

Direct Oral Anticoagulants (DOACs)
Heparins
Vitamin K Antagonists

Pulmonary Embolism Therapeutics Market By End-Use Sector (USD Billion, 2025-2035)

Hospitals
Clinics
Ambulatory Surgical Centers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035